B6CB-Tg(Vav1-NPM1/ALK)1Sudt/H
| Status | Available to order |
| EMMA ID | EM:01299 |
| Citation information | RRID:IMSR_EM:01299 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6CB-Tg(Vav1-NPM1/ALK)1Sudt/H |
| Alternative name | Vav-NPM/ALK |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(Vav1-NPM1/ALK)1Sudt |
| Gene/Transgene symbol | Tg(Vav1-NPM1/ALK)1Sudt |
Information from provider
| Provider | Suzanne Turner |
| Provider affiliation | The Babraham Institute, Babraham, Cambridge, CB2 4PB |
| Genetic information | The line VAV-NPM/ALK transgenic mice are heterozygous for the human oncogenic fusion protein nucleophosmin (nucleolar phosphoprotein B23)-anaplastic lymphoma kinase (NPM-ALK), under the regulation of the pan haemopoietic cell-specific Vav promotor. These mice develop B-cell lymphomas from 6 months of age. |
| Phenotypic information | Mice develop lymphoid tumours from 6 months of age. |
| Breeding history | Heterozygous VAV-NPM/ALK males are crossed to transgene-negative (C57BL/6J x CBA) F1 hybrid females. |
| References |
|
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Literature references
- Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.;Turner Suzanne D, Tooze Reuben, Maclennan Kenneth, Alexander Denis R, ;2003;Oncogene;22;7750-61; 14586401